Related Experiment Videos
Gene-modified tumor cells as cellular vaccine
1Department of Biological Sciences, University of Maryland Baltimore County 21250, USA.
Abstract:
The identification and characterization of many tumor antigens and the parallel explosion of knowledge of the cellular and molecular mechanisms of antigen recognition by the immune system have given renewed hopes that immunogenetherapy could be a promising modality to treat certain tumors. Many different novel strategies have been developed to derive genetically modified tumor cells and use them as cellular vaccines to induce useful antitumor immunity in a variety of animal tumor models. This review discusses induction of tumor immunity by injecting tumor cells that are genetically engineered to secrete various cytokines and to express major histocompatibility complex molecules and/or costimulatory molecules. While there has been a great success in inducing excellent antitumor immunity in a variety of tumor models, there are some difficulties and limitations in the application of these gene-modified tumor cells for the treatment of preexisting tumors. A number of improvements and modifications are already underway to overcome some of these problems.
Insights
Genetically engineered tumor cells secreting cytokines and expressing immune molecules show promise for cancer immunotherapy. While effective in models, challenges remain for treating existing tumors, with ongoing improvements underway.
Area of Science:
- Immunology
- Oncology
- Biotechnology
Background:
- Advances in tumor antigen identification and immune recognition mechanisms fuel cancer immunotherapy research.
- Gene-modified tumor cells are explored as cellular vaccines to elicit antitumor immunity.
Purpose of the Study:
- To review strategies for inducing tumor immunity using genetically engineered tumor cells.
- To discuss the successes and limitations of these approaches in preclinical models.
Main Methods:
- Engineering tumor cells to secrete cytokines.
- Modifying tumor cells to express major histocompatibility complex (MHC) and costimulatory molecules.
Main Results:
- Successful induction of potent antitumor immunity in various animal tumor models.
- Demonstrated efficacy of cytokine and MHC/costimulatory molecule-expressing tumor cells.
Conclusions:
- Genetically modified tumor cells offer a promising strategy for cancer immunotherapy.
- Current limitations exist for treating established tumors, necessitating further research and development.